Side-by-side comparison of AI visibility scores, market position, and capabilities
Las Vegas Sands Asia integrated resorts (NYSE: LVS) $11.4B FY2024 revenue; Sands China Macau $8.2B, Marina Bay Sands Singapore $2.93B (+14%), Londoner Macao renovation, competing with Galaxy and Melco.
Las Vegas Sands Corp. is a Las Vegas, Nevada-based integrated resort developer and operator — publicly traded on the New York Stock Exchange (NYSE: LVS) as an S&P 500 Consumer Discretionary component — developing, owning, and operating luxury integrated resort destinations in Macau, China (through Sands China Ltd., 69.4% owned subsidiary listed on Hong Kong Stock Exchange) and Singapore (Marina Bay Sands) through approximately 40,000 employees, following the 2021 sale of its Las Vegas properties (The Venetian, Palazzo, Las Vegas Sands Expo Center) to Apollo Global Management for $6.25 billion. In fiscal year 2024, Las Vegas Sands reported revenues of $11.4 billion (+5.7% year-over-year), with Macao Operations generating $8.2 billion ($4.49B at The Venetian Macao, $2.0B at Sands Macao, Four Seasons Macao, Parisian Macao, and Londoner Macao) and Singapore's Marina Bay Sands generating $2.93 billion (+14.3%). CEO Robert Goldstein leads Las Vegas Sands' strategy of Macau portfolio renovation and Singapore expansion: the Londoner Macao renovation ($2 billion+ investment transforming the former Sands Cotai Central into the Londoner Macao resort) completed its final tower renovations in 2024, while the Marina Bay Sands Tower 3 expansion (adding 1,000 hotel rooms, additional gaming floors, and a new arena for concerts and events) received Singapore government approval targeting 2028 completion.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.